Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Po... NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., June 01, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3...

#SilenceTherapeutics more p3 #rusfertide polycythemia vera data presented by competitor Protagonist+Takeda at ASCO, incl number of phlebotomies and % <45% hematocrit.

#SLN124 compares favorably in earlier studies.

finance.yahoo.com/news/protago...